Table 5 Comparison between CD38-negative and CD38-positive CLL patients:
From: Illuminating the impact of CD38-induced adenosine formation in B-cell lymphoma
CLL patients’ group | CD38 Negative | CD38 Positive | P-value | |
|---|---|---|---|---|
No. = 32 | No. = 16 | |||
Age (years) | Mean ± SD | 56.37 ± 8.1 | 59.56 ± 8.37 | 0.210• |
Range | 40–69 | 47–73 | ||
Sex | Females | 11 (34.4%) | 3 (18.8%) | 0.262* |
Males | 21 (65.6%) | 13 (81.3%) | ||
WBC (x 103/ul) | Median (IQR) | 60 (37.9–125) | 82 (56–105) | 0.319‡ |
Range | 10.5–531 | 16.2–428 | ||
LYMPH (x 103/ul) | Median (IQR) | 49.5 (25–96.5) | 69 (49–99.5) | 0.225‡ |
Range | 6.6–480 | 11–358 | ||
HB (g/dl) | Mean ± SD | 9.87 ± 2.94 | 9.89 ± 3.08 | 0.986• |
Range | 4.2–16.1 | 4.6–14 | ||
PLT (x 103/ul) | Median (IQR) | 122.5 (83–164) | 141.5 (68–243) | 0.577‡ |
Range | 16–352 | 10–291 | ||
BM.LYM (%) | Mean ± SD | 81.47 ± 14.42 | 77.75 ± 11.32 | 0.372• |
Range | 40–98 | 60–97 | ||
P53 mutation | Negative | 8 (72.7%) | 5 (100.0%) | 0.195* |
Positive | 3 (27.3%) | 0 (0.0%) | ||
sPD-L1 (ng/L) | Median (IQR) | 106.7 (68.72–147.45) | 422.5 (370.3–615.5) | 0.000‡ |
Range | 27.97–1081 | 100.9–1600 | ||
sPD-1 (ng/L) | Median (IQR) | 99.34 (63–133.5) | 461.5 (280–669.5) | 0.000‡ |
Range | 19.38–280.5 | 148–1300 | ||
sADO (ng/ml) | Median (IQR) | 536 (296–621.5) | 786.5 (678.5–1285.5) | 0.000‡ |
Range | 73–777 | 569–1700 | ||
Binet stages | A | 13 (40.6%) | 6 (37.5%) | 0.900* |
B | 8 (25.0%) | 5 (31.3%) | ||
C | 11 (34.4%) | 5 (31.3%) | ||
Risk stratification | Low | 13 (40.6%) | 6 (37.5%) | 0.900* |
Intermediate | 8 (25.0%) | 5 (31.3%) | ||
High | 11 (34.4%) | 5 (31.3%) | ||
